Back

Cardiovascular diseases and type 2 diabetes mellitus: high heart failure risk and low rate contraindications to SGLT2i

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Risk factors and prevention Diabetes and the Heart HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Vadim Medovchshikov

West Kazakhstan Marat Ospanov Medical University, Aktobe (Kazakhstan)

5 More presentations in this session

Presentation thumbnail
Eligibility for semaglutide according to the SELECT trial in a Portuguese cohort of acute coronary syndrome
Doctor V. Lopes (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Evaluation of the triglyceride-glucose index as a predictor of metabolic syndrome in elderly population. EVITGA-60 study
Doctor L. Calvo Betancourt (Bogota, CO)
Abstract Slides Video
Presentation thumbnail
Prevalence and incidence of heart failure in patients with type 2 diabetes mellitus. Results of the prospective DIABET-IC study
Doctor R. Gonzalez-Manzanares (Cordoba, ES)
Abstract Slides Video
Presentation thumbnail
CTO recanalization in type 2 diabetic patients: procedural and long-term prognosis
Doctor A. Silva (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Impact of dapagliflozin on exercise-induced hypertrophy: insights from a rodent model of athlete's heart
Doctor A. Olah (Budapest, HU)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors and prevention

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Prescribing SGLT2 inhibitors in acute heart failure: considerations for dysglycemia status, heart failure phenotype, and kidney function
thumbnail
Congress Presentation
Low levels of irisin predicted worsening kidney function in dapagliflozin-treated patients with chronic heart failure and concomitant type 2 diabetes mellitus
thumbnail
Congress Presentation
Predictors of kidney-related outcomes in chronic heart failure patients with concomitant type 2 diabetes mellitus treated with dapagliflozin

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources